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Prognostic Significance of Angiogenic Growth Factor Serum
Levels in Patients With Acute Coronary Syndromes
Christopher Heeschen, MD; Stefanie Dimmeler, PhD; Christian W. Hamm, MD; Eric Boersma, MD;
Andreas M. Zeiher, MD; Maarten L. Simoons, MD; on Behalf of the CAPTURE (c7E3 Anti-Platelet
Therapy in Unstable REfractory angina) Investigators
Background—In patients with acute coronary syndromes, compensatory processes are initiated, including angiogenesis
and endothelial regeneration of ruptured or eroded plaques. Angiogenic growth factors like vascular endothelial growth
factor (VEGF), hepatocyte growth factor (HGF), and basic fibroblast growth factor (bFGF) are upregulated during
ischemia. However, it is unknown whether their serum levels are related to clinical outcome.
Methods and Results—We measured VEGF, HGF, and bFGF levels in 1090 patients with acute coronary syndromes.
Angiographic evaluation was performed at baseline as well as death, and nonfatal myocardial infarctions were recorded
during 6-month follow-up. HGF and VEGF, but not bFGF, were significantly and independently associated with the
patients’ outcome. Patients with elevated VEGF serum levels suffered from adverse outcome (adjusted hazard ratio, 2.50
[1.52 to 4.82]; P0.002). VEGF elevation was associated with evidence of ischemia and was a significant predictor of
the effect of glycoprotein IIb/IIIa inhibition. In contrast, patients with high HGF levels had a significantly lower event
rate compared with patients with low HGF levels (adjusted hazard ratio, 0.33 [0.21 to 0.51]; P0.001). HGF levels did
not correlate with evidence of ischemia and did not predict the effect of abciximab. Intriguingly, however, HGF levels
significantly correlated with angiographically visible collateralization of the target vessel (22.4% versus 10.5%;
P0.001).
Conclusions—The angiogenic growth factors VEGF and HGF are independent predictors of the patients’ prognosis in
acute coronary syndromes. Whereas VEGF elevation correlated with the evidence of myocardial ischemia and indicated
an adverse outcome, HGF elevation was independent of ischemia and associated with improved collateralization as well
as a favorable prognosis. (Circulation. 2003;107:524-530.)
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In recent years, biochemical markers have contributed to abetter understanding of the underlying pathophysiology in
patients with acute coronary syndromes. Markers of myocar-
dial necrosis, most notably cardiac troponins, have become
valuable tools for risk stratification and optimizing treatment
strategies.1–5 During the consecutive repair phase after onset
of an acute coronary syndrome, compensatory processes are
initiated, including the formation of collateral circulation as
well as endothelial regeneration of ruptured or eroded
plaques.6 A variety of potent angiogenic growth factors have
been identified to stimulate neovascularization of ischemic
tissue.7,8 Among these, vascular endothelial growth factor
(VEGF), hepatocyte growth factor (HGF), and basic fibro-
blast growth factor (bFGF) have been experimentally shown
to improve tissue perfusion when administered exogenously
into ischemic tissue.9–11 In addition, both VEGF and HGF
have been shown to be upregulated endogenously after
myocardial infarction.12,13
However, it is unknown how serum levels of these angio-
genic growth factors relate to clinical outcome in patients
with acute coronary syndromes. In a previous study including
patients with myocardial infarction, baseline VEGF serum
levels were found to be elevated in patients with preinfarction
angina, a clinical feature associated with increased cardiac
risk, whereas HGF serum levels did not differ between
patients with and without preinfarction angina.14 Other stud-
ies for HGF revealed findings that are consistent with a
protective effect of HGF in patients with unstable coronary
heart disease.15–17 To investigate the prognostic significance
of angiogenic growth factors in patients with acute coronary
syndromes, we measured VEGF, HGF, and bFGF serum
levels in patients with acute coronary syndromes enrolled in
the CAPTURE trial (c7E3 Anti Platelet Therapy in Unstable
Refractory angina). The CAPTURE study was designed to
assess outcome in patients with refractory angina receiving
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either abciximab or placebo up to 24 hours before scheduled
percutaneous transluminal coronary angioplasty.18
Methods
Patients
The CAPTURE trial enrolled 1265 patients with refractory unstable
angina (61% males, aged 6110 years) between May 1993 and
December 1995. All CAPTURE patients had recurrent chest pain at
rest associated with electrocardiographic changes during treatment
with intravenous heparin and glyceryl trinitrate. All patients under-
went coronary angiography before randomization, indicating signif-
icant coronary artery disease with a culprit lesion 70% suitable for
angioplasty. The patients were randomly assigned to abciximab or
placebo; treatment was initiated within 2 hours of randomization.
Heparin was administered from before randomization until at least 1
hour after the percutaneous transluminal coronary angioplasty pro-
cedure and adjusted to achieve an activated partial thromboplastin
time between 2.0 and 2.5 times normal. For all patients, coronary
interventions were scheduled between 18 and 24 hours after begin-
ning study treatment. Primary end points of our study were mortality
and nonfatal myocardial infarction during the 6-month follow-up
period.18
Coronary Angiogram
All angiograms were assessed centrally by an Angiographic Com-
mittee at Cardialysis, Rotterdam, the Netherlands, with respect to
TIMI flow,19 characteristics of the culprit lesion according to the
AHA/ACC grading system, thrombus formation, and collateraliza-
tion. Presence of thrombus was strictly defined as filling defect or
haziness without calcification near the lesion visible on at least 2
orthogonal views or an embolus in the distal territory of the related
artery. Collateralization was categorized as undetectable (0), mini-
mal (1), partial (2), and complete retrograde filling (3).
Analytical Techniques
Blood samples were collected 8.7 hours (75% CI, 3.6 to 11.3) after
onset of symptoms. HGF,17 bFGF,20 and VEGF21 were measured by
ELISA (all from R&D systems). Detection limit for the respective
assays was 0.04 g/L, 0.05 ng/L, and 0.005 pg/L. Intra-assay
variation among triplicates was 7.5% for HGF, 8.2% for bFGF, and
6.6% for VEGF. It should be noted that HGF levels have been shown
to increase remarkably within 10 minutes after intravenous admin-
istration of heparin.17 For quantification of troponin T (TnT), a
one-step enzyme immunoassay based on electrochemiluminescence
technology (Elecsys 2010; Roche Diagnostics) was used.22 The
detection limit of this assay is 0.01 g/L, and the diagnostic
threshold level is 0.10 g/L. C-reactive protein (CRP) was measured
by N latex CRP mono tests, performed on a Behring BN II
Nephelometer (Behring Diagnostics).23 The detection limit of the
assay is 0.2 mg/L, and a calculated diagnostic threshold level of 10.0
mg/L was used.2
Statistical Methods
To distinguish between patients with different degrees of cardiac
risk, an exploratory data analysis was chosen. Patients were catego-
rized in quartiles according to the marker concentration. For each of
the 4 time points (24 hours, 72 hours, 30 days, and 6 months), a Cox
proportional-hazards regression analysis for the combined end points
death and nonfatal myocardial infarction was performed and patients
in the first quartile served as reference. Receiver operating charac-
teristics curve analyses over the dynamic range of the assays was
used to identify the threshold level providing highest predictive value
for risk-stratifying patients with acute coronary syndromes. The
impact of elevation of biochemical markers on patients’ outcome
was evaluated using a Cox proportional-hazards regression model,
adjusting for baseline prognostic factors (eg, electrocardiographic
findings, cardiac risk factors, age, and sex), use of heparin, and
randomized treatment.24
All results for continuous variables are expressed as medians with
95% confidence intervals. Comparisons between groups were ana-
lyzed by t test (two-sided) or ANOVA for experiments with more
than 2 subgroups. Post-hoc range tests and pairwise multiple com-
parisons were performed with the t test (two-sided) with Bonferroni
adjustment. Comparison of categorical variables was generated by
the Pearson 2 test. P0.05 was considered statistically significant.
Results
Serum samples were available in 1090 of 1265 patients
(86.2%). The baseline characteristics for the substudy popu-
lation were not different from the total study population. The
reduction of cardiac events in the abciximab group of the
substudy population was comparable to the entire CAPTURE
study population.
Elevated HGF Levels Predict Favorable Outcome
Overall HGF concentration did not correlate with TnT levels
(R0.002; P0.95) or CRP levels (R0.032; P0.30).
Patients were stratified into quartiles according to their
measured HGF levels, as follows: HGF 1, 2.50 g/L
(n260); HGF 2, 2.50 to 4.70 g/L (n278); HGF 3, 4.71 to
Figure 1. Association between HGF serum levels and cardiac
event rates. Patients in the upper 2 quartiles had a significantly
better outcome at 72-hour follow-up compared with patients in
the first quartile (A). Event rate curves continued to diverge dur-
ing the subsequent 6-month follow-up (B).
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6.80 g/L (n283); and HGF 4, 6.80 g/L (n269),
respectively. For the initial 24-hour period, the combined end
points mortality and nonfatal myocardial infarction tended to
be lower in the forth quartile compared with the first quartile
(P0.15) (Figure 1A). For the 72-hour follow-up, including
peri-interventional events, the event rates in the third and
forth quartiles were significantly lower compared with the
first quartile (P0.001 for both). During 30-day and 6-month
follow-up, the event rate curves additionally diverged, and
event rates remained significantly lower in the third and forth
quartile (P0.001 for all time points) (Figure 1B). Consistent
with these results, receiver operating characteristics curve
analysis indicated a threshold level of 4.7 g/L HGF for
maximized predictive value.
Therefore, the study population was dichotomized according to
the calculated threshold level of 4.7 g/L, resulting in 552 patients
with elevated HGF levels (50.6%). As depicted in Table 1, there
were no significant differences in the baseline characteristics of the
2 groups. Importantly, heparin dose and activity did not differ
between patients with high and low HGF serum levels. The
adjusted hazard ratios were 0.29 (95% CI, 0.16 to 0.53; P0.001)
for the 72-hour follow-up, 0.30 (0.18 to 0.52; P0.001) for the
30-day follow-up, and 0.33 (0.21 to 0.51; P0.001) for the 6-month
follow-up. Six-month cumulative event rates in patients with low
HGF levels were 14.9% versus 5.4% for patients with high HGF
levels (P0.001). This difference in event rates was not only driven
by a higher rate of nonfatal myocardial infarction but also by a
significantly higher mortality in patients with reduced HGF serum
levels (3.3% versus 0.7%; P0.002). Most notably, if HGF serum
levels were below the calculated threshold level, even in the absence
of myocardial necrosis as evidenced by normal TnT serum levels,
patients suffered from increased cardiac risk (adjusted hazard ratio,
8.20 [2.43 to 27.60]; P0.001). Regression analysis including a
term of interaction indicated no significant relation between HGF
status and benefit of treatment with abciximab (P0.98) (Figure 2).
Elevated VEGF Levels Predict Increased
Cardiac Risk
Patients were stratified into quartiles according to their
measured VEGF levels, as follows: VEGF 1, 0.137 pg/L
(n272); VEGF 2, 0.137 to 0.289 pg/L (n272); VEGF 3,
0.290 to 0.525 pg/L (n272); and VEGF 4, 0.525 pg/L
TABLE 1. Baseline Characteristics According to HGF, VEGF, and bFGF Status
HGF Low HGF High VEGF Low VEGF High bFGF Low bFGF High
No. 538 552 555 535 813 277
Male, % 72.3 70.1 69.4 72.0 70.6 74.1
Age, y 62.110.1 60.410.6 59.710.3 62.610.5 60.110.2 64.710.4
History, %
Angina 4 weeks 57.3 55.6 54.5 58.6 55.4 60.3
Infarction 30 days 21.0 18.0 18.6 20.5 19.6 19.5
Infarction 30 days 19.0 16.3 15.9 19.4 17.7 17.3
PTCA 18.5 16.6 16.1 19.0 17.3 18.4
CABG 3.4 3.5 3.5 3.4 3.7 2.5
Baseline ECG, %
Transient ST elevation 34.2 33.7 29.1 38.8* 33.6 35.0
ST depression 45.2 44.2 30.9 58.5* 43.2 49.5
T-wave inversion 47.3 54.6 52.5 49.5 50.6 52.3
Risk factors, %
Diabetes 10.4 9.9 8.2 12.1 10.0 10.5
Hypertension 35.4 38.5 36.2 37.7 36.9 37.2
Current smokers 38.3 42.5 41.2 39.6 40.3 40.8
Medication at baseline, %
Aspirin 98.1 98.0 98.1 98.1 98.1 98.2
Nitrates IV 98.9 99.6 99.2 99.3 99.6 97.8
-Blockers 64.0 62.7 63.5 63.2 63.0 64.3
ACE inhibitors 19.3 22.5 20.9 20.8 21.0 20.5
Ca antagonists 52.3 55.4 56.1 51.6 53.9 53.8
Heparin IV, % 99.4 98.3 99.3 98.5 98.5 100.0
Dose, IU per hour 148.835.9 143.641.3 146.538.7 144.338.5 144.935.8 150.250.4
aPTT, x-fold normal 2.310.41 2.250.39 2.290.42 2.270.38 2.250.39 2.360.48
Troponin T 0.1 g/L, % 35.5 40.6 18.9 57.9* 37.5 41.2
CK-MB mass 5.0 g/L, % 14.7 14.5 8.3 21.3* 13.7 17.3
*P0.01.
PTCA indicates percutaneous transluminal coronary angioplasty; CABG, coronary artery bypass graft; and ACE, angiotensin-
converting enzyme.
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(n274), respectively. VEGF concentration did positively
correlate with TnT levels (R0.43; P0.001). TnT levels
were significantly higher in the third and forth VEFG
quartiles (P0.001). VEGF levels also correlated with base-
line CRP levels (R0.15; P0.001). CRP levels were sig-
nificantly higher in the forth quartile (P0.009). For the
initial 24-hour period, the cardiac event rates did not differ
between the quartiles (Figure 3A). For the later time points
(72-hour, 30-day, and 6-month follow-up), the event rate was
significantly higher in the third (P0.001, P0.001, and
P0.001, respectively) and fourth quartile of VEGF serum
levels (P0.033, P0.015, and P0.003, respectively) (Fig-
ures 3A and 3B). Receiver operating characteristics curve
analysis indicated a threshold level of 0.3 pg/L VEGF for
maximized predictive value.
Therefore, the study population was dichotomized accord-
ing to this threshold level of 0.3 pg/L, resulting in 535
patients with VEGF levels equal or above 0.3 pg/L (49.1%).
Patients with high VEGF levels more frequently had ST-
segment depression, transient ST-segment elevation, recur-
rent ischemia (21.7% versus 14.3%; P0.005), CK-MB
elevation (21.3% versus 8.3%; P0.001), and troponin ele-
vation (57.9% versus 18.9%; P0.001) (Table 1). The
unadjusted hazard ratios were 3.82 for the 72-hour follow-up
(95% CI, 2.08 to 7.02; P0.001), 3.11 for the 30-day
follow-up (1.82 to 5.33; P0.001), and 2.03 for the 6-month
follow-up (1.35 to 3.06; P0.001). After adjusting for the
difference in baseline characteristics, VEGF levels remained
predictive for patient outcome (6-month follow-up: adjusted
hazard ratio 2.50 [1.52 to 4.82]; P0.002).
Regression analysis, including a term of interaction, indi-
cated a moderate relation between VEGF levels and benefit
of treatment with abciximab (P0.046). For patients with
VEGF values 0.3 pg/L, the event rates showed a significant
difference between placebo and abciximab treatment (13.0%
versus 6.4%, adjusted hazard ratio 0.46 [95% CI, 0.25 to
0.84] P0.007). For patients with VEGF values 0.3 pg/L,
the difference in event rates at 30-day follow-up between
placebo and abciximab group was similar but did not reach
statistical significance because of greater confidence intervals
(4.6% versus 2.4%; adjusted hazard ratio, 0.54 [95% CI, 0.20
to 1.30]; P0.11) (Figure 4).
Basic FGF Levels Are Not Related to
Cardiac Risk
Patients were stratified into quartiles according to their
measured basic FGF levels, as follows: bFGF 1, 5.40 g/L
(n271); bFGF 2, 5.40 to 9.20 g/L (n271); bFGF 3, 9.21
to 15.8 g/L (n271); and bFGF 4, 15.8 g/L (n277),
respectively. For all time points, no significant differences
were observed in the event rates between the quartiles. For
the 6-month follow-up, the crude event rates were as follows:
first quartile, 7.3%; second quartile, 7.3% (P1.00 compared
with the first quartile); third quartile, 8.5% (P0.86); and
fourth quartile, 13.3% (P0.15). Logistic regression analysis
using a threshold value of 15.8 g/L showed no significant
interaction between bFGF and cardiac risk for any selected
time point.
Figure 2. Adjusted hazard ratios (including 95% CIs) for treat-
ment with abciximab according to HGF status. Benefit of treat-
ment is defined as reduction of death or nonfatal myocardial
infarction at 30-day follow-up. Hazard ratios 1.0 indicate ben-
efit for treatment with abciximab compared with placebo. HGF
serum levels did not predict the effect of treatment with
abciximab.
Figure 3. Association between VEGF serum levels and cardiac
event rate. Patients in the upper 2 quartiles had a significantly
worse outcome compared with patients in the first quartile at
72-hour follow-up (A). This early difference in cardiac risk was
maintained at 6-month follow-up (B).
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Angiographic Features in Relation to Serum
Levels of Angiogenic Growth Factors
Lesion Characteristics
In 30.2% of patients with high HGF levels, type B2 or C
lesions were documented compared with 30.1% in patients
with low HGF levels (P0.92). Respective values for VEGF
were 30.9% versus 29.5% (P0.38) and for bFGF were
30.7% versus 30.1% (P0.93).
TIMI Flow
TIMI flow 1 was documented for 8.6% of patients with
high HGF levels compared with 9.2% for patients with low
HGF levels (P0.72). In contrast, TIMI flow 1 was
documented for 10.3% in patients with high VEGF levels
compared with 7.6% for patients with low VEGF levels
(P0.15). TIMI flow at baseline was normal in 55.2% of
patients with high VEGF levels versus 65.0% of patients with
low VEGF levels (P0.008). For bFGF, no differences with
respect to TIMI flow were documented.
Thrombus
Thrombus was visible in 7.6% of patients with high HGF
levels and in 5.9% of patients with low HGF levels (P0.35).
In patients with high VEGF levels, thrombus was visible at
the time of allocation in 7.8% of patients, compared with
5.9% for patients with low VEGF levels (P0.28). Respec-
tive values for bFGF were 6.5% and 7.0% (P0.92).
Visible Collateral Formation
Collaterals were detectable in 22.4% of patients with high
HGF levels but in only 10.5% of patients with low HGF
levels (P0.001). Partial or complete retrograde filling was
observed in 10.0% of patients with high HGF levels versus
5.6% of patients with low HGF levels (P0.001). For
patients with high VEGF levels, collaterals were detectable in
17.3% of the patients, compared with 15.3% for patients with
low VEGF levels (P0.64). Respective values for bFGF
were 14.4% and 14.0% (P0.69).
Multivariate Analysis
To delineate a potential independent prognostic significance
of individual angiogenic growth factor serum levels, a mul-
tivariate analysis of the placebo group was performed includ-
ing the biochemical markers TnT, CRP, HGF, and VEGF, the
use of heparin, as well as baseline characteristics that re-
vealed significant predictive value in a univariate model.
Detection of collateral formation on the baseline angiogram
did not predict patients’ outcome. For the end points death
and nonfatal myocardial infarction at 30-day and 6-month
follow-up, none of the established risk factors was an inde-
pendent predictor after the dichotomized biochemical mark-
ers were introduced into the model (Table 2). TnT, HGF, and
VEGF remained the only independent significant predictors
of patients’ outcome, whereas CRP lost significance after the
other biochemical markers were introduced into the model.
Discussion
The findings of the present study establish HGF serum levels
as a novel independent prognostic determinant of clinical
outcome in patients suffering from acute coronary syn-
dromes. Elevated HGF serum levels are associated with a
profoundly reduced incidence of death and nonfatal myocar-
dial infarction. Most notably, in patients without troponin
elevation, reduced HGF serum levels identify a subgroup of
patients that suffers from significantly increased cardiac risk
(adjusted hazard ratio, 8.20 [2.43 to 27.60]; P0.001). In
contrast, elevated VEGF serum levels are associated with
worse clinical outcome in patients with acute coronary
syndromes, whereas bFGF serum levels do not provide any
significant information for risk stratification in these patients.
HGF, initially regarded as a growth factor specific to
hepatocytes, is now well established to be a multipotent
growth factor whose receptor c-met is not only expressed in
the normal epithelium of almost every tissue but also in
different cell types, including cardiac myocytes, endothelial
Figure 4. Adjusted hazard ratios (including 95% CIs) for treat-
ment with abciximab according to VEGF. Benefit of treatment is
defined as reduction of death or nonfatal myocardial infarction
at 6-month follow-up. Hazard ratios 1.0 indicate benefit for
treatment with abciximab compared with placebo. The benefit
of abciximab treatment was more pronounced in patients with
VEGF serum levels 0.3 pg/L.
TABLE 2. Multivariate Cox Proportional-Hazards Regression
Model of the Placebo Group for Death and Nonfatal Myocardial
Infarction at 6-Month Follow-Up
Variable
Hazard
Ratio 95% CI P
Sex 0.85 0.65 to 1.08 0.10
Age 65 y 1.52 0.95 to 2.65 0.16
Diabetes mellitus 1.15 0.843 to 1.46 0.64
Hypercholesterolemia 0.90 0.68 to 1.13 0.59
ST-segment depression 1.33 0.82 to 1.98 0.36
Complex coronary lesions 1.15 0.73 to 2.84 0.63
Visible thrombus 1.22 0.54 to 3.61 0.92
Heparin dose 1.02 0.79 to 1.43 0.99
TnT 0.1 g/L 1.82 1.25 to 2.59 0.03
CRP 10.0 mg/L 1.36 0.82 to 1.95 0.23
HGF 4.7 g/L 0.30 0.16 to 0.58 0.001
VEGF 0.3 pg/L 2.34 1.52 to 4.28 0.004
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cells, and hematopoietic cells.25 The general activities of
HGF were found to be mitogenesis, motogenesis (enhance-
ment of cell motility),25 morphogenesis, and promotion of
cell survival.26 Accordingly, HGF can potentially modify
several important processes contributing to the obvious ben-
eficial effects of high HGF serum levels in patients with acute
coronary syndromes. HGF has been shown to be a potent
angiogenic factor, suggesting an important function during
ischemic damage.27 Indeed, our data showed more frequently
partial or complete retrograde filling of the target vessel via
collaterals in patients with elevated HGF levels. However, the
presence of collaterals and subsequent retrograde filling of
the target vessel was not a significant independent predictor
of patients’ outcome, suggesting that other mechanism than
collateralization may also contribute to the protective effect
of elevated HGF levels.
In this respect, several experimental studies provide evi-
dence that HGF may also play a role for the protection from
myocardial ischemia/reperfusion injury. Ono et al13 demon-
strated the upregulation of HGF and its receptor in an
experimental model of myocardial infarction, indicating that
the HGF system may be part of a defense mechanism that
occurs with acute myocardial ischemia. Importantly, expres-
sion of HGF also rapidly increases in other than the ischemic
tissue, whereas the HGF receptor is selectively upregulated in
the ischemic myocardium. Given that HGF is a strong
promoter of cell survival, it is tempting to speculate that HGF
exerts its cardioprotective function via cardiotrophic effects
on ischemic myocardium. Indeed, Nakamura et al15 observed
that administration of HGF to rats with ischemia/reperfusion
injury resulted in a significant reduction of myocardial
apoptosis and infarct area and better cardiac function,
whereas neutralizing antibodies to HGF resulted in pro-
foundly increased infarct size and enhanced mortality attrib-
utable to cardiac failure.
In addition, vascular endothelial cells are a major target of
HGF.13 HGF was experimentally shown to restore ischemia-
induced vascular dysfunction to maintain endothelium-
dependent regulation of coronary blood flow.17 Moreover,
HGF augments the growth of hematopoietic progenitor
cells.28 Recent data demonstrate that a subset of hematopoi-
etic progenitor cells importantly contributes to endothelial
regeneration after endothelial denudation.29 Thus, besides its
potent angiogenic action, HGF may induce regeneration of
the endothelial layer because of its direct antiapoptotic and
cell survival promoting effects on endothelial cells. Taken
together, elevated HGF serum levels may contribute to the
observed improved clinical outcome in patients with acute
coronary syndromes via a combination of cardioprotective
functions on ischemic myocardium and vasculoprotective
functions by enhancing endothelial regeneration of ruptured
or eroded plaques. Thus, therapeutic interventions that en-
hance HGF serum levels could potentially be beneficial in
patients with acute coronary syndromes.
A potential limitation for the use of HGF for risk stratifi-
cation of patients with acute coronary syndromes at the time
of presentation may be that serum levels of HGF are
significantly elevated within minutes of heparin infusion. All
patients in the CAPTURE trial were taking heparin when
serum samples were collected. It is important to notice that
heparin use, dose, and activity did not differ between patients
with high and low HGF serum levels (Table 1). Because
heparin is standard therapy in patients with acute syndromes,
blood sampling should be scheduled after the initiation of
treatment.
In contrast to the favorable effects of elevated HGF serum
levels, elevated VEGF serum levels were significantly asso-
ciated with worse clinical outcome. Increased VEGF levels
have been observed as an early response to myocardial
ischemia or infarction.12 Because VEGF is activated by the
transcription factor hypoxia-induced factor-1, elevation of
VEGF levels is regarded as an early adaptation of the
myocardium to deprivation of blood flow.12,13 Indeed, in
CAPTURE patients, VEGF serum levels were linked to TnT
elevation, impaired TIMI flow, and clinical evidence of
myocardial ischemia. Thus, VEGF serum levels measured
during the acute phase of an ischemic event may actually
represent a temporal marker of acutely jeopardized myocar-
dium and, thus, provide important prognostic information. In
this respect, the results of our study also demonstrate that
VEGF is a powerful and independent predictor of patients’
outcome after acute coronary syndromes.
In addition, recent studies suggested that activated platelets
are a major source of VEGF release.21 Consistent with this
finding, we found a more pronounced treatment effect of the
potent platelet inhibitor abciximab in patients with elevated
VEGF serum levels (Figure 4). Combined with previous
reports demonstrating a beneficial effect of aggressive plate-
let inhibition by the glycoprotein IIb/IIIa inhibitor abciximab
in patients with elevated troponin levels30 and a significant
correlation between troponin T and VEGF serum levels, these
findings are consistent with the hypothesis that elevated
VEGF serum levels in patients with acute coronary syn-
dromes may predict an increased risk attributable to myocar-
dial cell necrosis secondary to thrombus formation at the
culprit lesion and distal embolization in the coronary vascular
bed. Surprisingly, however, difference in the detectable
thrombus formation between patients with high and low
VEGF serum levels was not significant. However, it should
be appreciated that angiography is not a very sensitive
method for the detection of thrombus, particularly when very
strict criteria are applied, as in the present study. In contrast,
no interaction was found between HGF serum levels and the
effect of abciximab. These findings indicate that, in contrast
to elevated VEGF serum levels, elevated HGF levels do not
merely reflect an increased risk of acute myocardial ischemia
but rather mediate cardiovascular protective effects indepen-
dent of thrombus formation at the culprit lesion.
In our study population, bFGF serum levels did not serve
as a significant predictor of patients’ outcome. Patients with
stable coronary heart disease, enrolled in a previous study,31
had median bFGF serum levels of 2.4 g/L (95% CI, 0.2 to
13.8), whereas present patients with acute coronary syn-
dromes enrolled in the CAPTURE trial had significantly
higher bFGF serum levels with 12.1 g/L (95% CI, 1.2 to
72.5) (P0.003). However, we did not find a significant
difference in cardiac risk among patients with acute coronary
syndromes when categorized according to bFGF serum lev-
Heeschen et al Angiogenic Growth Factors in Acute Coronary Syndromes 529
els. These data suggest that, although bFGF was experimen-
tally shown to increase collateral circulation and restore
myocardial perfusion and function,32,33 alterations in endog-
enous bFGF serum levels during acute coronary syndromes
do not appear to exert a significant protective effect.
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